CO5640041A2 - Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias - Google Patents
Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratoriasInfo
- Publication number
- CO5640041A2 CO5640041A2 CO03102140A CO03102140A CO5640041A2 CO 5640041 A2 CO5640041 A2 CO 5640041A2 CO 03102140 A CO03102140 A CO 03102140A CO 03102140 A CO03102140 A CO 03102140A CO 5640041 A2 CO5640041 A2 CO 5640041A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cycloalkyl
- alkenyl
- group
- groups
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title abstract 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000414 obstructive effect Effects 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 239000000812 cholinergic antagonist Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- Una combinación inhalada de un inhibidor selectivo de PDE4 y un agente anticolinérgico, con la condición de que el agente anticolinérgico no sea una sal de tiotropio.2.- Una combinación de acuerdo con la reivindicación 1, caracterizada porque el inhibidor selectivo de PDE4 es un compuesto de la fórmula (I) o una sal o solvato farmacéuticamente aceptable de él, endonde:R1 es H, alquilo (de C1-C6), alcoxi (de C1-C6), alquenilo (deC1-C6), fenilo, -N(CH3)2, cicloalquilo (de C3-C6), cicloalquilo(de C3-C6) alquilo (de C1-C3) o acilo (de C1-C6), en donde los grupos alquilo, fenilo o alquenilo pueden ser sustituidos con hasta dos grupos -OH, alquilo (de C1-C3) o CF3 o hasta tres halógenos; R2 y R3 se seleccionan independientemente del grupo formado por H, alquilo (de C1-C14), alcoxi (de C1-C7)alquilo (de C1-C7), alquenilo (de C2-C14), cicloalquilo (de C3-C7), cicloalquilo (de C3-C7) cicloalquilo (de C3-C7) alquilo (de C1-C2), un grupo (CH2)n heterocíclico (de C4-C7) saturado o insaturado en donde n es 0, 1 o 2 que contiene como el heteroátomo uno o dos del grupo formado por oxígeno, azufre, sulfonilo, nitrógeno y NR4 en donde R4 es H o alquilo (de C1-C4); o un grupo de la fórmula (II) : en donde a es un número entero de 1 a 5; b y c son 0 o 1; R5 es H, -OH, alquilo (de C1-C5), alquenilo (de C2-C5), alcoxi (de C1-C5), cicloalcoxi (de C3-C6), halógeno, -CF3, -CO2R6, -CONR6R7, -NR6R7, -NO2, o -SO2NR6R7 en donde R6 y R7 son cada uno independientemente H, o alquilo (de C1-C6); Z es -O-, -S-, -SO2-, -CO-, o -N(R8)- en donde R8 es H o alquilo (de C1-C4); e Y es alquileno (de C1-C5) o alquenileno (de C2-C8) optativamente sustituido con hasta dos grupos alquilo (de C1-C7) o cicloalquilo (de C3-C7); en donde cada uno de los grupos alquilo, alquenilo, cicloalquilo, alcoxialquilo o hetercíclico pueden ser sustituidos con 1 a 14, preferentemente 1 a 5 grupos alquilo (de C1-C2), CF3 o halo; y R9 y R10 se seleccionan cada uno independientemente del grupo formado por H, alquilo (de C1-C6), alcoxi (de C1-C8), arilo (de C8-C10) y ariloxi (de C8-C10).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29360601P | 2001-05-25 | 2001-05-25 | |
| GB0129396A GB0129396D0 (en) | 2001-12-07 | 2001-12-07 | Pharmaceutical combination |
| GB0210240A GB0210240D0 (en) | 2002-05-03 | 2002-05-03 | Pharmaceutical combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5640041A2 true CO5640041A2 (es) | 2006-05-31 |
Family
ID=27256347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO03102140A CO5640041A2 (es) | 2001-05-25 | 2003-11-19 | Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20040147544A1 (es) |
| EP (1) | EP1395288A1 (es) |
| JP (1) | JP2005508861A (es) |
| KR (1) | KR20040007605A (es) |
| CN (1) | CN1511042A (es) |
| AP (1) | AP2003002909A0 (es) |
| BG (1) | BG108382A (es) |
| BR (1) | BR0209992A (es) |
| CA (1) | CA2446613A1 (es) |
| CO (1) | CO5640041A2 (es) |
| CR (1) | CR7152A (es) |
| CZ (1) | CZ20033150A3 (es) |
| EE (1) | EE200300585A (es) |
| HU (1) | HUP0400037A2 (es) |
| IL (1) | IL158776A0 (es) |
| MA (1) | MA27027A1 (es) |
| MX (1) | MXPA03010162A (es) |
| NO (1) | NO20035204D0 (es) |
| NZ (1) | NZ529335A (es) |
| OA (1) | OA12610A (es) |
| PA (1) | PA8546001A1 (es) |
| PL (1) | PL367085A1 (es) |
| SK (1) | SK14312003A3 (es) |
| TN (1) | TNSN03123A1 (es) |
| WO (1) | WO2002096463A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| US20040058950A1 (en) * | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| CA2519679C (en) * | 2003-03-28 | 2012-08-28 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| EP1610788A1 (en) * | 2003-03-28 | 2006-01-04 | ALTANA Pharma AG | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| PL1713471T3 (pl) * | 2004-02-06 | 2012-06-29 | Meda Pharma Gmbh & Co Kg | Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych |
| JP2007520509A (ja) * | 2004-02-06 | 2007-07-26 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | 抗コリン薬による、又は抗ヒスタミン薬、ホスホジエステラーゼ４、又はコルチコステロイドとの組み合わせによる鼻炎治療薬 |
| WO2005074918A1 (en) | 2004-02-06 | 2005-08-18 | Benzstrasse 1 D-61352 Bad Homburd | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd |
| WO2005102344A1 (ja) * | 2004-04-27 | 2005-11-03 | Kyowa Hakko Kogyo Co., Ltd. | 医薬組成物 |
| DE602004015788D1 (de) * | 2004-08-19 | 2008-09-25 | Rottapharm Spa | Verwendung von Phenylbenzamide-derivaten zur Behandlung von chronisch-obstruktiver Lungenerkrankung (COPD) |
| JP4991693B2 (ja) | 2005-03-16 | 2012-08-01 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤 |
| GB0511066D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| KR100696432B1 (ko) * | 2005-08-31 | 2007-03-19 | 김용환 | 건강진단용 팬티 |
| WO2007045980A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type iv inhibitors |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| JP5107933B2 (ja) | 2005-12-21 | 2012-12-26 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 炎症性疾患の治療に使用する、抗コリン作用薬類、β２−アドレナリン受容体のアゴニスト類、抗ロイコトリエン（ロイコトリエン受容体のアンタゴニスト）類、グルココルチコイド類および／またはＰＤＥ４阻害剤類の新規配合薬 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552407A (en) * | 1993-06-11 | 1996-09-03 | New York University Medical Center | Anhydroecgonine compounds and their use as anticholinergic agents |
| JP3107827B2 (ja) * | 1995-06-06 | 2000-11-13 | ファイザー・インコーポレーテッド | トリサイクリック５，６−ジヒドロ−９Ｈ−ピラゾロ［３，４−ｃ］−１，２，４−トリアゾロ［４，３−ａ］ピリジン類 |
| US20020193393A1 (en) * | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
-
2002
- 2002-05-24 US US10/478,755 patent/US20040147544A1/en not_active Abandoned
- 2002-05-24 CA CA002446613A patent/CA2446613A1/en not_active Abandoned
- 2002-05-24 EE EEP200300585A patent/EE200300585A/xx unknown
- 2002-05-24 PL PL02367085A patent/PL367085A1/xx not_active Application Discontinuation
- 2002-05-24 EP EP02750977A patent/EP1395288A1/en not_active Withdrawn
- 2002-05-24 BR BR0209992-6A patent/BR0209992A/pt not_active IP Right Cessation
- 2002-05-24 JP JP2002592972A patent/JP2005508861A/ja not_active Withdrawn
- 2002-05-24 WO PCT/EP2002/005726 patent/WO2002096463A1/en not_active Application Discontinuation
- 2002-05-24 HU HU0400037A patent/HUP0400037A2/hu unknown
- 2002-05-24 PA PA20028546001A patent/PA8546001A1/es unknown
- 2002-05-24 CN CNA028104986A patent/CN1511042A/zh active Pending
- 2002-05-24 IL IL15877602A patent/IL158776A0/xx unknown
- 2002-05-24 CZ CZ20033150A patent/CZ20033150A3/cs unknown
- 2002-05-24 SK SK1431-2003A patent/SK14312003A3/sk not_active Application Discontinuation
- 2002-05-24 NZ NZ529335A patent/NZ529335A/en unknown
- 2002-05-24 OA OA1200300304A patent/OA12610A/en unknown
- 2002-05-24 KR KR10-2003-7015352A patent/KR20040007605A/ko not_active Application Discontinuation
- 2002-05-24 AP APAP/P/2003/002909A patent/AP2003002909A0/en unknown
- 2002-05-24 MX MXPA03010162A patent/MXPA03010162A/es unknown
-
2003
- 2003-07-08 TN TNPCT/EP2002/005726A patent/TNSN03123A1/en unknown
- 2003-11-19 CO CO03102140A patent/CO5640041A2/es not_active Application Discontinuation
- 2003-11-19 CR CR7152A patent/CR7152A/es not_active Application Discontinuation
- 2003-11-20 MA MA27408A patent/MA27027A1/fr unknown
- 2003-11-24 NO NO20035204A patent/NO20035204D0/no not_active Application Discontinuation
- 2003-11-24 BG BG108382A patent/BG108382A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005508861A (ja) | 2005-04-07 |
| IL158776A0 (en) | 2004-05-12 |
| NO20035204D0 (no) | 2003-11-24 |
| PA8546001A1 (es) | 2003-12-30 |
| EP1395288A1 (en) | 2004-03-10 |
| CA2446613A1 (en) | 2002-12-05 |
| EE200300585A (et) | 2004-04-15 |
| MXPA03010162A (es) | 2004-03-10 |
| TNSN03123A1 (en) | 2005-12-23 |
| HUP0400037A2 (hu) | 2004-04-28 |
| CZ20033150A3 (cs) | 2004-06-16 |
| WO2002096463A1 (en) | 2002-12-05 |
| OA12610A (en) | 2006-06-09 |
| KR20040007605A (ko) | 2004-01-24 |
| BR0209992A (pt) | 2004-04-06 |
| AP2003002909A0 (en) | 2003-12-31 |
| BG108382A (bg) | 2004-12-30 |
| MA27027A1 (fr) | 2004-12-20 |
| US20040147544A1 (en) | 2004-07-29 |
| NZ529335A (en) | 2005-09-30 |
| SK14312003A3 (sk) | 2004-08-03 |
| PL367085A1 (en) | 2005-02-21 |
| CN1511042A (zh) | 2004-07-07 |
| CR7152A (es) | 2004-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5640041A2 (es) | Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias | |
| CY1121699T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR044909A1 (es) | Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
| AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR035497A1 (es) | Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos | |
| AR038882A1 (es) | Compuestos que modulan la actividad de ppar y composicion farmaceutica que los contiene | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR057408A1 (es) | Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento | |
| AR086144A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
| AR063101A1 (es) | Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. | |
| AR041055A1 (es) | Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| AR061651A1 (es) | Analogos de piridina ii | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
| DOP2006000088A (es) | Compuestos utiles en terapia | |
| AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |